|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.020 USD | -4.04% |
|
-5.05% | +22.55% |
| 06-02 | Karyopharm Therapeutics Inc. - Special Call | |
| 06-02 | Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis | MT |
| Market Cap | 204M 178M 165M 155M 290M 19.29B 292M 1.96B 759M 9.49B 767M 751M 32.97B | P/E 2026 * |
-2.17x | P/E 2027 * | -2.91x |
|---|---|---|---|---|---|
| Enterprise Value | 457M 399M 369M 346M 648M 43.16B 652M 4.38B 1.7B 21.24B 1.72B 1.68B 73.77B | EV / Sales 2026 * |
3.33x | EV / Sales 2027 * | 1.32x |
| Free-Float |
95.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Karyopharm Therapeutics Inc.
| 1 day | -4.04% | ||
| 1 week | -5.05% | ||
| Current month | -0.88% | ||
| 1 month | +20.75% | ||
| 3 months | +16.69% | ||
| 6 months | +29.97% | ||
| Current year | +22.55% |
| 1 week | 8.9 |  | 9.83 |
| 1 month | 7.72 | | 10.22 |
| Current year | 5 | | 10.99 |
| 1 year | 3.65 | | 10.99 |
| 3 years | 3.51 | | 31.48 |
| 5 years | 3.51 | | 220.95 |
| 10 years | 3.51 | | 444.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 58 | 2021-05-02 |
Lori Macomber
DFI | Director of Finance/CFO | 55 | 2025-01-02 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barry Greene
BRD | Director/Board Member | 62 | 2012-12-31 |
| Director/Board Member | 61 | 2013-03-31 | |
Garen Bohlin
BRD | Director/Board Member | 78 | 2013-10-02 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-20 | Free | Director | 15,508 | 0.0688% | ||
| 05-20 | Free | Director | 15,508 | 0.0688% | ||
| 05-20 | Free | Director | 15,508 | 0.0688% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.04% | -5.05% | +103.15% | -70.52% | 204M | |
| +0.33% | -0.36% | +18.76% | -22.11% | 62.05B | |
| +0.20% | -9.17% | +58.39% | +196.56% | 54.52B | |
| -3.92% | +37.40% | +37.40% | +37.40% | 41.55B | |
| +7.62% | +8.19% | -51.27% | -59.11% | 39.06B | |
| -1.05% | -1.73% | +55.35% | -33.92% | 29.02B | |
| +3.50% | +28.15% | +151.81% | -50.31% | 25.38B | |
| -0.78% | -9.50% | +43.87% | +55.34% | 19.62B | |
| +1.74% | -0.39% | -2.93% | +113.90% | 16.89B | |
| -0.05% | +0.23% | +61.48% | +101.93% | 15.89B | |
| Average | +0.36% | +2.52% | +47.60% | +26.92% | 30.42B | |
| Weighted average by Cap. | +0.78% | +1.72% | +36.71% | +35.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 137M 120M 111M 104M 195M 12.95B 196M 1.31B 509M 6.37B 515M 504M 22.13B | 155M 135M 125M 117M 220M 14.65B 222M 1.49B 577M 7.21B 583M 570M 25.04B |
| Net income | -121M -106M -97.73M -91.49M -172M -11.42B -173M -1.16B -449M -5.62B -454M -445M -19.52B | -135M -117M -109M -102M -191M -12.69B -192M -1.29B -499M -6.25B -505M -494M -21.7B |
| Net Debt | 253M 221M 204M 191M 359M 23.87B 361M 2.42B 939M 11.75B 950M 929M 40.8B | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-18 | 9.020 $ | -4.04% | 492,124 |
| 26-06-17 | 9.400 $ | +3.30% | 283,580 |
| 26-06-16 | 9.100 $ | -5.60% | 322,103 |
| 26-06-15 | 9.640 $ | +1.47% | 172,462 |
| 26-06-12 | 9.500 $ | +5.56% | 564,583 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KPTI Stock
Select your edition
All financial news and data tailored to specific country editions
